Celebrating the success of Stilla technologies in raising 16 million euros from Illumina Ventures

Beijing deep blue cloud biotechnology as Stilla Technologies Asia Pacific technology demonstration and service center warmly celebrates Stilla Technologies France lllumina Ventures 16 million euros financing.

New York (GenomeWeb) - on November 20, 2018, Stilla Technologies announced that it had completed A series A financing round of 16 million euros ($18.3 million) led by lllumina Ventures. Backers of the deal include Kurma Partners, LBO France, BNPParibas Developpement. Paris Saclay Seeds&ldinvest Partners, Nick from lllumina Ventures, as part of the financing.Naclerio, Philippe Peltier of Kurma Partners and Philippe Chambon of LBO France have joined the Stilla event instead of seed investors.

The Naica Crystal automatic microdroplet chip digital PCR system developed by Stilla Technologies has high sensitivity, high precision and unique use.As the design core of the whole system, the innovative 2D Sapphire chip of cutting edge microfluidics integrates the generation and amplification of microdroplets in a single instrument, and has a unique three-color detection channel. Since 2016, three color of this innovative digital PCR testing system on the market in Europe and the United States, in 2017 formally entering the China market, by the vast number of clinical research, diagnosis reagent development enterprise wide recognition in the field of molecular detection and diagnosis, such as the degree of automation and integration, effective droplets of outstanding performance, 25000-30000, as well as powerful and user friendly software interface, is extremely satisfied with feedback on the market. Stilla is working on a six-color fluorescent channel reader designed to be easy to use.

Stilla said he will use this round of financing to promote the commercial development and clinical application of the NaicaCrystal fully automatic microdroplet chip digital PCR system. Specifically, Stilla will work to accelerate sales of the Naica  Crystal fully automated digital PCR system, launch a second generation solution and begin clinical validation, particularly in oncology, said Dr. Remi Dangla, founder of Stilla Technologies.

"With the Naica Crystal automated droplet chip digital PCR system, researchers around the world are building a new generation of high-precision genetic tests for cancer diagnosis, prenatal testing, gm testing and liquid biopsies," Dangla said.

"The fully automated Naica Crystal droplet digital PCR system, developed and launched by the stilla Technologies team in Europe and Asia, is excellent and seed financing is very limited," Naclerio said in a statement. With these additional resources, we believe Stilla Technologies can become a global player in digital PCRLeader and lowest cost platform for liquid biopsies.

The funding of lllumina Ventures means that Stilla technologies will have more development in the clinical field, especially for providing tools and technologies for detecting genetic characteristics in the early stage of cancer treatment, and integrating liquid biopsy into the clinical workflow as one of the confirmation methods of personalized solutions, so that clinicians can better understand!The effectiveness of the treatment plan, and the next personalized treatment plan for patients has a guiding significance.

About llumina Ventures

Lllumina Ventures, founded in 2016 and headquartered in California, USA, is an independently run venture capital firm focused on healthcare institutions.Institutions. It invests in early-stage companies and focuses on areas such as life science research, including genomics, health care, agriculture and environmental sciences, public safety and personal health.

About French Stilla Technologies, detailed information please click: http://www.cycloudbio.com/product/1887.html

About the deep blue cloud details please click: http://www.cycloudbio.com/product/type/2702-6760-1.html